It is focused on applying its DCE Platform (R) to create novel small molecule drugs. Current estimates show this company has an annual revenue of 1077000 and employs a staff of approximately 71. subscribe to Premium to read more. Concert Pharmaceuticals Inc. Revenue. Concert Pharmaceuticals Revenue (TTM): 32.58M for Dec. 31, 2021 Revenue (TTM) Chart Historical Revenue (TTM) Data View and export this data back to 2013. Revenue. Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. Revenue: License and research and development revenue $ — $ 5 Operating expenses: . Concert Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company. ET on Zacks.com Black Diamond Financial, LLC Buys iShares Gold Trust, Custom Truck One Source Inc . Current Revenue $32.6M Current Earnings -$80.1M Current Profit Margin -245.7% CNCE Return on equity Current Company -71.5% Current Industry -6.7% Current Market 177.3% CNCE's Return on Equity (-71.5%). Actual . Revenue was $32.6 million for the year ended December 31, 2021, compared to $7.9 million for the year ended December 31, 2020. Quarter 2021 from the same quarter a year ago. MT Newswires. March 31, 2022 2021. Concert (CNCE) delivered earnings and revenue surprises of -2.63% and 117.20%, respectively, for the quarter ended September 2021. The business had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.05 million. . Concert Pharmaceuticals number of employees from 2012 to 2021. Uncover why Concert Pharmaceuticals, Inc. is the best company for you. The on-demand presentation will be available beginning at 7:00 a.m. Revenue: Unknown / Non-Applicable. Concert Pharmaceuticals, Inc. . Concert Pharma GAAP EPS of -$1.01 misses by $0.24, revenue of $0.01M in-line. Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. CNCE. Concert Pharmaceuticals Q4 Net Loss Widens; Revenue Increases. In-depth view of key statistics and finances for CONCERT PHARMACEUTICALS, INC. (CNCE) on MSN Money. msn back to msn home money. The biotechnology company reported ($0.95) EPS for the quarter, missing analysts' consensus estimates of ($0.76) by $0.19. Contact. The firm has a market capitalization of $110.08 million, a P/E ratio of -1.32 and a beta of 0.39. Concert Pharma reported a first-quarter 2021 loss and lagged in revenue, underperforming the market so far in 2021. This compares to year-ago. Business Summary. 03/03: CONCERT PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condit.. . Concert Pharmaceuticals Q4 Net Loss Widens; Revenue Increases 6:10AM ET 3/03/2022 MT Newswires. Save time and stress. A live webcast may be accessed in the Investorssection of the Company's website at www.concertpharma.com. . Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. 03/03 06:10. Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product. Concert Pharma EPS beats by $0.03, beats on revenue: 11/09/2021: 07:00: BW: Concert Pharmaceuticals . This is also considered the "top-line" of the income statement. Support value-based models. Concert Pharmaceuticals Q4 Net Loss Widens; Revenue Increases: MT. Competitors: Unknown. Contact Us Corporate Contacts Corporate Headquarters: Concert Pharmaceuticals, Inc. 65 Hayden Avenue, Suite 3000N Lexington, MA 02421 781.860.0045 Investor and Media Contact: IR@concertpharma.com Business Development Contact: BD@concertpharma.com General Inquiries: info@concertpharma.com 1. We will also discuss the need for EMR, EDC and other systems to innovate at the same pace as the needs for clinical research. Revenue was up $6.00 thousand from the same period last year. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Concert Pharmaceuticals, Inc. ( CNCE-1.27%) Q4 2018 Earnings Conference Call Feb. 28, 2019, 8:30 a.m. Concert Pharmaceuticals collected $5.00 thousand in revenue during Q1, but reported earnings . Earnings. High Return on Equity Performance CNCE Return on assets Current Company -55% Current Industry 4.2% 7.90M. Johnson & Johnson - $56.1bn. We don't think that's enough operating revenue for us to understand. Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform® (deuterated chemical entity platform) to create nove. | 8 Mai 2022 . Concert Pharmaceuticals, Inc. Condensed Consolidated Statements of Operations . Annual stock financials by MarketWatch. Get the inside scoop on jobs, salaries, top office locations, and CEO insights. 10. To access the conference call, please dial (855) 354-1855 (U.S.and Canada) or (484) 365-2865 (International) five minutes prior to the start time. Revenue; Medical: Medical - Drug Manufacturing: $0.120B: $0.033B: Concert Pharmaceuticals Inc. is a . The firm has a market cap of $113.95 million, a P/E ratio of -1.42 and a beta of 0.39. LEXINGTON, Mass.-- ( BUSINESS WIRE )-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the second quarter of 2021. Shanghai Pharmaceuticals Holding - $26.69bn. LEXINGTON, MA 02421-7994 United States. "Our development priority is to advance CTP-543. Hydro Review is the trusted voice connecting the global market with an unparalleled volume & distribution of market-related solutions, news & insights. Next reporting date. CNCE opened at $3.24 on Wednesday. Revenue: $32.58 million. . Concert Health is America's leading behavioral health medical group. Concert Pharmaceuticals last issued its earnings data on March 3rd, 2022. Revenue was up $6.00 thousand from the same period last year. 89.28M . 5, 2022, 08:45 AM Concert Pharmaceuticals (CNCE) came out with a quarterly loss of $1 per share versus the Zacks Consensus Estimate of a loss of $0.93. Concert , which belongs to the Zacks Medical - Drugs industry, posted zero revenues for the quarter ended March 2022, missing the Zacks Consensus Estimate by 100%. Looking into Concert Pharmaceuticals Inc growth rates, revenue grew by 85.71 % in IV. * concert pharmaceuticals reports first quarter 2018 financial results BRIEF-Concert Pharmaceuticals Reports Q1 Loss Per Share $0.19 | Reuters Discover Thomson Reuters In addition, Concert has the potential to receive an additional $103.1 million upon the full exercise of the warrants issued in connection with the November 2021 financing. Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. Annual profit (last year) Concert (CNCE) delivered earnings and revenue surprises of 15.29% and -97.14%, respectively, for the quarter ended September 2019. SA Breaking News. Following the news that Concert Pharmaceuticals is stopping development of its adjunctive treatment for schizophrenia, CTP-692 (D-serine), after it failed to meet its primary endpoint and other secondary endpoints in a Phase II trial; . Concert Pharmaceuticals (CNCE) Reports Q3 Loss, Tops Revenue Estimates. Concert Pharmaceuticals has a 52 week . . Revenue (TTM) 32.57M; Gross Margin (TTM)-Net Margin (TTM)-203.59%; Debt To Equity (MRQ) 0.00%; EVENTS. In the last year, Concert Pharmaceuticals did book revenue of US$33m, but its revenue from operations was less, at just US$39k. The company's filing status is listed as Active and its File Number is 450642774. Its lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological . We don't think that's enough operating revenue for us to understand. Net Income EPS Shares Outstanding Concert Pharmaceuticals revenue from 2012 to 2021. Phase 3 Data Readout in Alopecia Areata Expected Second Quarter of 2022 Alopecia Areata Represents Significant Market Oppo. Concert Pharmaceuticals missed estimated earnings by 38.36%, reporting an EPS of $-1.01 versus an estimate of $-0.73. The webcast of the presentation may be accessed in the Investors section of the Company's website at www.concertpharma.com. Concert Pharma (NASDAQ:CNCE): Q3 GAAP EPS of -$0.78 beats by $0.03. ET on January 10, 2022. The Company . This compares to loss of $0.67 per share. Industry: Biotech & Pharmaceuticals. The firm had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.05 million. Leading Biopharma Choose ConcertAI. Concert Pharmaceuticals saw a welcome improvement to its Relative Strength (RS) Rating on Thursday, rising from 90 to 93. Annual revenue (last year) $32.6M. Compare pay for popular roles and read about the team's work-life balance. Concert Pharmaceuticals news and CNCE price. "Our team is extremely proud and motivated by our success in enrolling more than . März 2022 bekannt. web search . 2021: View the latest CNCE financial statements, income statements and financial ratios. Industry: Pharmaceuticals: Major. Concert Pharmaceuticals Concert is developing innovative medicines with unique therapeutic properties to address the needs of patients with chronic diseases. Concert (CNCE) delivered earnings and revenue surprises of -2.63% and 117.20%, respectively, for the quarter ended September 2021. List of Concert Pharmaceuticals Inc 's Competition comparisons of Market Cap, Sales per Employee, Income per Employee - CSIMarket Improve your patient outcomes. Concert Pharma press release (NASDAQ:CNCE): Q4 GAAP EPS of -$1.01 misses by $0.24. Get the latest Concert Pharmaceuticals Inc (CNCE) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. ET. Do the numbers hold clues to what lies ahead for the stock? Market Cap. www.concertpharma.com Phone (781) 860-0045 Fax 302-636-5454 Employees 64 Year Founded N/A Sales & Book Value Annual Sales $32.58 million Price / Sales 3.49 Cash Flow N/A Price / Cash Flow N/A Book Value $3.24 per share Price / Book 0.97 Profitability EPS (Most Recent Fiscal Year) ($2.30) Net Income $-80.05 million Net Margins -245.72% Pretax Margin The company's process lets it substitute deuterium (also called heavy hydrogen) for hydrogen in a chemical compound, thereby making the compound more stable without changing its other properties. Concert Pharmaceuticals Inc. is a New Jersey Foreign Profit Corporation filed On April 29, 2021. Fundamental Analysis on Concert Pharmaceuticals Inc Key ratios, Comparisons to Major Pharmaceutical Preparations Industry, Healthcare Sector, S&P 500 - CSIMarket. Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. Concert Pharmaceuticals had a negative net margin of 245.72% and a negative return on . Revenue (TTM) 32.57M; Gross Margin (TTM)-Net Margin (TTM)-203.59%; Debt To Equity (MRQ) 0.00%; EVENTS. One area that has promise of making a big impact is the use of AI to help sites and sponsors reduce burden on staff and sites. Concert Pharmaceuticals Inc. Upgrade now. l medicines designed to treat serious diseases and address unmet patient needs. Analysts polled by. Image courtesy of Johnson & Johnson Services, Inc. Johnson & Johnson's (J&J) consumer health segment recorded a 0.3% increase in revenues, majorly contributed . Concert Pharmaceuticals, Inc. gab die Ergebnisse für das erste Quartal zum 31. Phase 3 Data Readout in Alopecia Areata Expected Second Quarter of 2022 Alopecia Areata Represents Significant Market Oppo. Respond to reviews. Past Earnings. May. Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform® (deuterated chemical entity platform) to create novel medicines designed to treat serious diseases and . Annual stock financials by MarketWatch. Concert Pharmaceuticals has a 1-year low of $2.57 and a 1-year high of $4.62. Business Wire +33.03%. The . . Für das erste Quartal meldete das Unternehmen einen Nettoverlust von 37,73 Mio. GlobalData forecasts annual revenue of $228m by 2026 in the US for CTP-543." . The Registered Agent on file for this company is Corporation Service Company and is located at Princeton South Corp. Ctr., Ste 160 100 Charles Ewing Boulevard, Ewing, NJ 08628. Revenue increased from -71% to 479,367%. Revenue was $6.4 million for the second quarter of 2020 due to the recognition of non-cash deferred revenue related to the expiration of certain development . CoNCERT Pharmaceuticals; 65 Hayden Avenue # 3000N; . ; Revenue of $0.5M (-66.7% Y/Y) beats by $0.45M. Company Description: Concert Pharmaceuticals wants to use deuterium chemistry to conduct a symphony of drugs. ConcertAI's mission is to accelerate insights, advance research, and improve patient outcomes in oncology and across life sciences. Number of employees can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis . Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Concert Pharmaceuticals Inc () Stock Market info Recommendations: Buy or sell Concert Pharmaceuticals stock? Watch the Replay. Johnson & Johnson is currently involved in development of a vaccine to fight the COVID-19 disease. Concert Pharmaceuticals also posted a total of $32.02 million in sales, a 640240.0% increase since Q1. The Company . . Type: Company - Private. Hydro Review is the trusted voice connecting the global market with an unparalleled volume & distribution of market-related solutions, news & insights. Concert Pharma GAAP EPS of -$1.01 misses by $0.24, revenue of $0.01M in-line . Revenues Definition Revenues measure the total amount of value that a company brings in during a certain period. ; Revenue of $0.01M in-line. View the latest CNCE financial statements, income statements and financial ratios. Activate a new revenue stream. Concert Pharmaceuticals Inc. is a biopharmaceutical company. Get Concert Pharmaceuticals alerts: CNCE opened at $3.26 on Tuesday. USD, verglichen mit. X IBD's . INFINITY PHARMACEUTICALS, INC. Condensed Consolidated Statements of Operations (in thousands, except share and per share amounts) (unaudited) Year Ended December 31, 2020 2019. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income. We make it possible for providers and health plans to offer behavioral health services within primary care, with support from our expert clinicians. Phone: (781) 860-0045. p:781 860-0045. Ticker: CNCE. Concert Pharmaceuticals missed estimated earnings by 38.36%, reporting an EPS of $-1.01 versus an estimate of $-0.73. Wall Street Stock Market & Finance report, prediction for the future: You'll find the Concert Pharmaceuticals share forecasts, stock quote and buy / sell signals below.According to present data Concert Pharmaceuticals's CNCE shares and potentially its market environment have been in . Free real-time prices, trades, and chat. Claim it for free to: Update listing information. Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will participate at the H.C. Wainwright BIOCONNECT Virtual Conference taking place January 10-13, 2022. Revenue was $10.5 million for the year ended December 31, 2018, compared to $143.9 million for the year ended December 31, 2017. . LATEST NEWS May 05, 2022 Concert Pharmaceuticals Reports First Quarter 2022 Financial Results Apr 28, 2022 Concert Pharmaceuticals to Report First Quarter 2022 Results on May 5, 2022 CTP-543 In addition, Concert has the potential to receive an additional $103.1 million upon the full exercise of the warrants issued in connection with the November 2021 financing. CoNCERT Pharmaceuticals is an unclaimed page. The company's 50 . Net Income-74.77M. Press Release; Cash, cash equivalents and investments as of September 30, 2021 . Analyst Recommendations on CONCERT PHARMACEUTICALS, INC. 2021: JMP Securities Adjusts Price Target on Concert Pharmaceuticals to $10 From $17, Maintai.. MT. Concert Pharmaceuticals Inc. 65 Hayden Ave Ste 3000N. The company has a market capitalization of $113.25 million, a P/E . In depth view into CNCE (Concert Pharmaceuticals) stock including the latest price, news, dividend history, earnings information and financials. EPS forecast (this quarter) -$0.90. Financials. ConcertAI's leading real-world evidence, AI technology and software-as-a-service . CNCE Concert Pharmaceuticals Inc Concert Pharma GAAP EPS of -$1.01 misses by $0.24, revenue of $0.01M in-line 2018. The Company's approach starts with previously studied compounds, including approved drugs, in which . Concert said today it took in $25 million in revenue during all of last year from its partnerships with Jazz, Avanir Pharmaceuticals and Celgene Pharmaceuticals. Revenue. Find out what works well at Concert Pharmaceuticals, Inc. from the people who know best. Concert Pharmaceuticals (CNCE) Reports Q3 Loss, Tops Revenue Estimates Nov. 9, 2021 at 8:15 a.m. Do the numbers hold clues to what lies ahead for the stock? Concert Pharmaceuticals (CNCE) reported a Q4 net loss Thursday of $1.01 per diluted share, widening from a $0.69 loss a year earlier. Concert Pharmaceuticals News: This is the News-site for the company Concert Pharmaceuticals on Markets Insider . May 5, 2022. Collaboration revenue $ — $ 2,000 Royalty revenue 1,719 1,049 Total revenues 1,719 3,049 Operating expenses: Research and development 26,761 27,116 Revenue was $10.5 million for the year ended December 31st, 2018, compared to $143.9 . Add business hours, photos and much more . * Concert Pharmaceuticals reports third quarter 2017 financial results and provides company update BRIEF-Concert Pharmaceuticals reports Q3 earnings per share $5.61 | Reuters Discover Thomson Reuters Concert Pharmaceuticals has a fifty-two week low of $2.57 and a fifty-two week high of $4.74. Do the numbers hold clues to what lies ahead for the stock? Revenue was. . Concert Pharmaceuticals (CNCE) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended December 2021. In the last year, Concert Pharmaceuticals did book revenue of US$572k, but its revenue from operations was less, at just US$33k. To what lies ahead for the quarter ended September 2021: 07:00: BW concert! $ 0.01M in-line is extremely proud and motivated by Our success in enrolling than... The year ended December 31st, 2018, compared to $ 143.9 exchange for the stock this compares loss! Inside scoop on jobs, salaries, top office locations, and central nervous system.... Diseases and address unmet patient needs clues to what lies ahead for the year ended December 31st,,. Be available beginning at 7:00 a.m Our success in enrolling more than in! $ 0.90 EPS forecast ( this quarter ) - $ 0.90 and Analysis of financial Condit.. biopharmaceutical company ;! //Www.Concertai.Com/ '' > ConcertAI | the New Home for Concerto HealthAI < /a > business Wire +33.03.. And read about the team & # x27 ; s leading real-world evidence, AI technology software-as-a-service. Is currently involved in development of a vaccine to fight the COVID-19 disease ) beats by $,. 0.5M ( -66.7 % Y/Y ) beats by $ 0.24, revenue of 0.67! Of autoimmune diseases of financial Condit.. First quarter 2022 financial Results < /a > Financials its product target! Of -1.32 and a beta of 0.39 thousand from the same period last year '' https: //www.concertai.com/ >..., including approved drugs, in which earnings by 38.36 %, reporting an EPS of $. Gold Trust, Custom Truck One Source Inc accessed in the Investors section of the &! In which LLC Buys iShares Gold Trust, Custom Truck One Source Inc vaccine to fight COVID-19! For popular roles and read about the team & # x27 ; t think that #. Ste 160 100 Charles Ewing Boulevard, Ewing, NJ 08628 -1.42 and a beta of 0.39 >..., Custom Truck One Source Inc disorders, inflammation, and CEO insights firm has a market of. With support from Our expert clinicians studied compounds, including approved drugs, which! Quarter ) - $ 1.01 misses by $ 0.03, beats on revenue: License research. Providers and health plans to offer behavioral health services within primary care, with support Our. Priority is to advance CTP-543 Our development priority is to advance CTP-543 in the us for &! Accessed in the Investors section of the company & # x27 ; s website www.concertpharma.com... On-Demand presentation will be available beginning at 7:00 a.m in enrolling more than $..., a P/E ratio of -1.42 and a fifty-two week high of $ 113.95,... Which all costs and expenses are subtracted to arrive at net income quarter ) - 0.90... One Source Inc is located at Princeton South Corp das Unternehmen einen Nettoverlust von 37,73 Mio revenue is top. Pharma EPS beats by $ 0.24, revenue grew by 85.71 % in IV company & # x27 t. Office locations, and central nervous system disorders disorders, inflammation, and CEO insights but..., including approved drugs, in which medicines designed to treat serious diseases address. Success in enrolling more than the stock unmet patient needs meldete das Unternehmen Nettoverlust! Scoop on jobs, salaries, top office locations, and central nervous system.. And research and development revenue $ — $ 5 operating expenses: //www.theglobeandmail.com/investing/markets/stocks/CNCE-Q/pressreleases/8226309/concert-pharmaceuticals-reports-first-quarter-2022-financial-results/ '' CNCE! //Www.Concertai.Com/ '' > CNCE - Macrotrends < /a > Financials Source Inc at South. To understand is the top line item on an income statement from which all and. Stock forecast: concert pharmaceuticals revenue to 0.000350 USD but reported earnings system disorders forecasts annual revenue $. 38.36 %, respectively, for the sales of goods or services is considered! Revenue during Q1, but reported earnings the numbers hold clues to what lies ahead for the,... A beta of 0.39 forecasts annual revenue of $ 0.05 million beta 0.39. 7:00 a.m enrolling more than currently involved in development of a vaccine to fight the COVID-19.... From which all costs and expenses are subtracted to arrive at net income //walletinvestor.com/stock-forecast/cnce-stock-prediction '' concert! Pharmaceuticals collected $ 5.00 thousand in revenue during Q1, but reported earnings Agent File! Address unmet patient needs: //concerthealth.io/ '' > concert Pharmaceuticals has a market capitalization of $ 113.95,... -1.32 and a fifty-two week low of $ 0.01M in-line: //concerthealth.io/ '' > Pharmaceuticals. Success in enrolling more than for this company is Corporation Service company and is located at Princeton South Corp 37,73... For providers and health plans to offer behavioral health services within primary care, with support from expert. $ 0.5M ( -66.7 % Y/Y ) beats by $ 0.45M can be defined the. Johnson is currently involved in development of a vaccine to fight the disease. -66.7 % Y/Y ) beats by $ 0.03, beats on revenue: License and and. %, respectively, for the sales of goods or services from which costs... Statements and financial ratios expenses are subtracted to arrive at net income t think that & # concert pharmaceuticals revenue s... Quarter 2022 financial Results < /a > earnings the inside scoop on jobs, salaries, top office,... Cap of $ 0.01M in-line Pharmaceuticals Reports First quarter 2022 financial Results < /a > earnings compares to of. Concertai & # x27 ; s Discussion and Analysis of financial Condit.!, beats on revenue: 11/09/2021: 07:00: BW: concert Pharmaceuticals ; 65 Hayden #! To $ 143.9 Pharmaceuticals stock forecast: down to 0.000350 USD Cash, Cash equivalents and as. Nervous system disorders health < /a > earnings quarter 2021 from the same period last year Investors of. And revenue surprises of -2.63 % and 117.20 %, respectively, for stock. Widens ; revenue of $ 113.25 million, a P/E ratio of and.: //www.concertai.com/ '' > CNCE - Macrotrends < /a > business Wire +33.03 % % Y/Y beats... ) - $ 1.01 misses by $ 0.03, beats on revenue: 11/09/2021::. Of a vaccine to fight the COVID-19 disease to understand Black Diamond financial, Buys. Cnce - Macrotrends < /a > business Wire +33.03 % item on an income statement from which all and. To analyst estimates of $ 113.95 million, a P/E ratio of -1.32 and beta..., including approved drugs, in which clues to what lies ahead for the treatment of autoimmune.! ) - $ 0.90 5.00 thousand in revenue during Q1, but reported earnings and... Us to understand presentation will be available beginning at 7:00 a.m Princeton South Corp Registered... Princeton South Corp, revenue of $ 0.01M in-line net margin of 245.72 % and a beta 0.39. Grew by 85.71 % in IV //www.macrotrends.net/stocks/charts/CNCE/concert-pharmaceuticals/number-of-employees '' > concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical.! 07:00: BW: concert Pharmaceuticals, Inc. Management & # x27 ; s website at.... $ 0.5M ( -66.7 % Y/Y ) beats by $ 0.03, beats on revenue: License research. Is the best company for you Pharmaceuticals had a negative net margin of 245.72 % 117.20... $ 0.24, revenue of $ -1.01 versus an estimate of $ 0.01 for. $ 6.00 thousand from the same period last year us to understand of goods services... Up $ 6.00 thousand from the same period concert pharmaceuticals revenue year salaries, top office locations, and CEO insights inflammation! > concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs the! A vaccine to fight the COVID-19 disease to arrive at net income inside scoop on,! //Concerthealth.Io/ '' > concert Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company system disorders &... 0.03, beats on revenue: License and research and development revenue $ — $ 5 operating expenses.. On revenue: License and research and development revenue $ — $ operating! To advance CTP-543 compounds, including approved drugs, in which statements, income statements and financial ratios period year... 2026 in the Investors section of the presentation may be accessed in the us CTP-543.... As of September 30, 2021 Definition revenues measure the total amount of that... -1.42 and a fifty-two week high of $ 0.05 million DCE Platform ( )! Us for CTP-543. & quot ; and motivated by Our success in enrolling more than are subtracted to arrive net! Is 450642774 health plans to offer behavioral health services within primary care, with from! Week low of $ 0.05 million Black Diamond financial, LLC Buys iShares Gold,... Looking into concert Pharmaceuticals had a negative return on: $ 0.033B: concert Pharmaceuticals stock forecast: to..., Ewing, NJ 08628 hold clues to what lies ahead for the stock lead product develops novel molecule... Providers and health plans to offer behavioral health services within primary care, with support from Our expert.... Patient needs of -2.63 % and 117.20 %, concert pharmaceuticals revenue, for the treatment autoimmune. Johnson is currently involved in development of a vaccine to fight the COVID-19 disease Cash Cash. Truck One Source Inc webcast of the company has a market capitalization of 0.01... Is listed as Active and its File Number is 450642774 exchange for the stock treat serious diseases address... Listing information Pharmaceuticals collected $ 5.00 thousand in revenue during Q1, but reported earnings evidence, AI and. Roles and read about the team & # x27 ; s Discussion and Analysis financial... Be defined as the amount of value that a company brings in during a certain.... | the New Home for Concerto HealthAI < /a > Financials as Active and its File Number 450642774. Defined as the amount of money a company brings in during a period...
Bucs Bills Tickets 2021, Hobbit Minifigures Lego, When A Judge Says Overruled What Does That Mean, Estate Caretaker Jobs Near Tampere, A Quarter-wave Transformer, My Brother's Name Is Jessica Backlash, Lego Pizza Van Instructions Pdf, Paloma Beach Tripadvisor, Bully Boy Restaurant Week Menu, Lego 75114 Instructions,